Loading clinical trials...

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer | Clinical Trials | Clareo Health

TERMINATED

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer: A Multicenter Observational Cohort Study

NCT05352217•Stiftung Swiss Tumor Institute

View on ClinicalTrials.gov

Summary

The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.

Detailed Description

The observational study will examine different follow-up modalities for ovarian cancer patients with the ultimate goal of improving follow-up strategies for an improved well-being and better clinical outcomes. The primary objective is to quantify the effects of conservative clinical diagnostics by collecting symptoms via ePRO in addition to intensive diagnostics (CA-125 testing, imaging diagnostics) during follow-up, on survival, time to clinical recurrence and well-being.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Women aged ≥ 18 years
•Between diagnosis and the first follow-up visit after the end of their antineoplastic treatment (systemic therapy or surgical treatment) for ovarian cancer.
•German, English, French, or Italian speaking
•Personal smartphone (iOS or Android system); one of the latest three main versions

Exclusion Criteria

•Patients whose compliance must be questioned, e.g. due to a psychiatric disorder, private life situation or insufficient knowledge on smartphone use and do not have a suitable caregiver to assist them with symptom reporting.

Locations (4)

Spital Limmattal Frauenklinik

Schlieren, Canton of Zurich, Switzerland

Gynäkologische Onkologie Spital Zollikerberg

Zollikerberg, Canton of Zurich, Switzerland

Praxis für Gynäkologie und Geburtshilfe

Zurich, Switzerland

Interdisziplinäre Medizin Zürich (IMZ)

Zurich, Switzerland

Key Dates

Start Date

December 13, 2021

Primary Completion Date

November 13, 2023

Completion Date

November 13, 2023

Last Updated

April 22, 2024

Enrollment

ACTUAL participants

Conditions

Patient Reported Outcome MeasuresOvarian Neoplasms

Interventions

Mobile app ovarian cancer followup (ePRO)

DEVICE

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

At-home Breast Oncology Care Delivered With E-health Solutions

Establishment of a Tumor Bank for Tissue Samples